SK Bioscience Co Ltd (302440) - Cash Flow Conversion Efficiency
Based on the latest financial reports, SK Bioscience Co Ltd (302440) has a cash flow conversion efficiency ratio of 0.010x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩20.65 Billion ≈ $14.00 Million USD) by net assets (₩2.07 Trillion ≈ $1.41 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of SK Bioscience Co Ltd for the company's overall valuation and market capitalisation.
SK Bioscience Co Ltd - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how SK Bioscience Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
SK Bioscience Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SK Bioscience Co Ltd ranked by their cash flow conversion efficiency. Explore 302440 cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhejiang DiAn Diagnostics Co
SHE:300244
|
0.069x |
|
Nations Technologies Inc
SHE:300077
|
-0.129x |
|
Intapp Inc
NASDAQ:INTA
|
0.028x |
|
Zhejiang Weixing New Building Materials Co Ltd
SHE:002372
|
0.075x |
|
Fulltech Fiber Glass
TWO:1815
|
0.023x |
|
Stock Yards Bancorp Inc
NASDAQ:SYBT
|
0.051x |
|
Westshore Terminals Investment Corp
TO:WTE
|
0.150x |
|
Polaris Bay Group Co Ltd
SHG:600155
|
0.037x |
Annual Cash Flow Conversion Efficiency for SK Bioscience Co Ltd (2018–2024)
The table below shows the annual cash flow conversion efficiency of SK Bioscience Co Ltd from 2018 to 2024. View latest SK Bioscience Co Ltd stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩2.02 Trillion ≈ $1.37 Billion |
₩-128.02 Billion ≈ $-86.76 Million |
-0.063x | -467.52% |
| 2023-12-31 | ₩1.70 Trillion ≈ $1.15 Billion |
₩29.35 Billion ≈ $19.89 Million |
0.017x | +124.01% |
| 2022-12-31 | ₩1.74 Trillion ≈ $1.18 Billion |
₩-124.96 Billion ≈ $-84.68 Million |
-0.072x | -121.41% |
| 2021-12-31 | ₩1.60 Trillion ≈ $1.09 Billion |
₩536.59 Billion ≈ $363.64 Million |
0.335x | -26.47% |
| 2020-12-31 | ₩263.79 Billion ≈ $178.77 Million |
₩120.22 Billion ≈ $81.47 Million |
0.456x | +386.10% |
| 2019-12-31 | ₩232.73 Billion ≈ $157.72 Million |
₩21.82 Billion ≈ $14.79 Million |
0.094x | +32.58% |
| 2018-12-31 | ₩210.73 Billion ≈ $142.81 Million |
₩14.90 Billion ≈ $10.10 Million |
0.071x | -- |
About SK Bioscience Co Ltd
SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally. Its product portfolio includes Skycellflu, a cell cultured influenza surface antigen vaccine; Skycellflu 4-ga pre-filled syringe; pneumococcal vaccine for adult and infant; Skyzoster, a shingles virus vaccine; and Sky Baricella for the preve… Read more